Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:28 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
NCT04614766 · David Bushnell · PHASE1/PHASE2 · withdrawn · last registry update 2024-04-29 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Azedra withdrawn from US market” | – | Registry record, David Bushnell |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SSTR5 in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-04Phase 3 first posted: SWOG Cancer Research Network, Lanreotide (NCT06807437)
- 2025-01-24Results posted on the registry: Advanced Accelerator Applications, arginine/lysine (NCT04524442)
- 2025-01-20Phase 3 first posted: Novartis Pharmaceuticals, Octreotide LAR (NCT06784752)
- 2025-01-13Also stopped (terminated): Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Capecitabine + Lu-PRRT (NCT02736448)
- 2024-11-27Results posted on the registry: Advanced Accelerator Applications, Lutetium [177Lu] oxodotreotide/dotatate (NCT04711135)
- 2024-10-26Also stopped (withdrawn): University of Chicago, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT) (NCT05610826)
- 2024-10-10Results posted on the registry: Advanced Accelerator Applications, Lutathera + 30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot) (NCT03972488)
- 2024-10-01Results posted on the registry: Ipsen, Lanreotide autogel (NCT04852679)
- 2023-10-19Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., 68Ga-DOTATOC (NCT06091748)
- 2023-06-01Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide (NCT05884255)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision